HBM Partners
Dr. Alexander Asam, MBA, currently serves as a Partner at HBM Partners AG since 2007 and holds observer roles on the Board of Directors at Aculys Pharma and Swixx BioPharma. With extensive experience in biotechnology, Dr. Asam has held board positions at various companies across Europe, the US, and Canada since 1999, including significant roles at Mineralys Therapeutics, Inc. and APR Applied Pharma Research. Notable past board engagements include membership at Arcutis Biotherapeutics and Corvidia Therapeutics, the latter being acquired by Novo Nordisk for up to USD 2.1 billion. Dr. Asam earned an MBA in Finance & Strategy from Aston Business School and a PhD in Chemistry from Ruprecht-Karls-Universität Heidelberg.
This person is not in the org chart
This person is not in any teams
HBM Partners
HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies. HBM Partners has a team of experienced professionals to source, analyse and engage in investments in biopharma, medical devices and diagnostics industries. HBM Partners has a track-record of over 100 investments that resulted so far in significant value creation by more than 60 trade sales and IPOs since inception. HBM Partners is regulated by FINMA and advises SIX listed HBM Healthcare Investments and further specialised public and private equity investment products.